Bioavailability.

The aim and objective of the present work is to design and develop fast disintegrating tablets of Amlodipine Besylate to improve the patient compliance and  desired bioavailability by selected delivery system by following immediate release mechanism. The drawbacks of the tablets can be overcome using methods involved in modified dissolving tablets, oral  dissolving  tablets (MDT) or orally disinter grating tablets (ODT) ; which started as an alternative oral dosage forms. To achieve successful delivery of drug , it  needs to be protected from degradation,  drug release to be improved and increase absorption. For this objective and to have the rapid  uptake of drug in solution form by rapid disintegrating formulation to be expected to have better  Therapeutic effect of both drugs in the gastrointestinal tract. The research objective   of the present work understands the novel advancements that are made in oral fast disintegration preparations incorporated anti hypertensive drug like Amlodipine Besylate using combination of super disintegrants.

The present research work focuses on improving the bioavailability of the anti osteoporotic drug Risedronate Sodium. This drug belongs to BCS class III which implies that it is permeability rate limited. Hence an attempt was made to reduce the particle size to nano dimensions using ionotropic gelation technique. In this technique, chitosan was used as the polymer and sodium Tri poly Phosphate was used as the cross linking agent. The resulting nanoparticles were optimized using 32 full factorial design and characterized for their entrapment efficiency, percent yield, in vitro diffusion studies. The particle size and zeta potential was found out and surface morphology was studied using Scanning electron microscopy. The in vivo studies clearly showed a marked improvement in the bioavailability of the nanoparticles as compared to the plain drug suspension.

This study investigated the spherical agglomeration of itraconazole for enhanced drug dissolution rate and bioavailability at various polymers percentage like 0.2%, 0.4%and 0.6% with Soluplus®, HPMC and PEG-4000 by simple stirring at 900 r.p.m. (The spherical agglomerates(SA) were dried powdered and with method followed by characterized by differential scanning calorimetry and X-ray powder diffraction. The SAs of itraconazole were also evaluated by drug content study, solubility study and in-vitro dissolution study. The pharmacokinetic studies of the formulations and pure itraconazole were evaluated i.e. Cmax, Tmax and AUC   in vivo study by pharmacokinetic model on wistar rats.

There are various approaches for the delivery of therapeutic substance to the target site in a controlled release fashion. One such approach is using microspheres as carriers for drugs or active pharmaceutical compound. However, the success of this drug delivery system is limited due to their short residence time at the site of absorption. Mucoadhesive microspheres can be tailored to adhere to any mucosal tissue including those found in stomach, thus offering the possibilities of localized as well as systemic controlled release of drugs. This article presents the  advantages of Mucoadhesive microsphere, mechanism, theories involved in mucoadhesion, factor that affect the mucoadhesion, polymer in Mucoadhesive drug delivery system, methodology of preparation of Mucoadhesive microsphere, method of evaluation and their applications in drug delivery. Mucoadhesive drug delivery systems promises several advantages that arise from localization at a given target site, prolonged residence time at the site of drug absorption and an intensified contact with the mucosa increasing the drug concentration gradient.